Nothing Special   »   [go: up one dir, main page]

WO2017136562A3 - Bispecific binding proteins for pd-l1 and kdr - Google Patents

Bispecific binding proteins for pd-l1 and kdr Download PDF

Info

Publication number
WO2017136562A3
WO2017136562A3 PCT/US2017/016230 US2017016230W WO2017136562A3 WO 2017136562 A3 WO2017136562 A3 WO 2017136562A3 US 2017016230 W US2017016230 W US 2017016230W WO 2017136562 A3 WO2017136562 A3 WO 2017136562A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding proteins
bispecific binding
kdr
bispecific
human
Prior art date
Application number
PCT/US2017/016230
Other languages
French (fr)
Other versions
WO2017136562A2 (en
Inventor
Zhenping Zhu
Dan Lu
Original Assignee
Kadmon Corporation, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kadmon Corporation, Llc filed Critical Kadmon Corporation, Llc
Priority to EA201891732A priority Critical patent/EA201891732A1/en
Priority to JP2018540412A priority patent/JP2019506863A/en
Priority to EP17748163.7A priority patent/EP3411068A4/en
Priority to CN201780021304.8A priority patent/CN109310755A/en
Publication of WO2017136562A2 publication Critical patent/WO2017136562A2/en
Publication of WO2017136562A3 publication Critical patent/WO2017136562A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Provided are bispecific binding proteins such as bispecific antibodies that bind to both human PD-L1 and human KDR. The bispecific binding proteins are useful for treating diseases and conditions characterized by immunosuppression and/or excessive angiogenesis.
PCT/US2017/016230 2016-02-02 2017-02-02 Bispecific binding proteins for pd-l1 and kdr WO2017136562A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EA201891732A EA201891732A1 (en) 2016-02-02 2017-02-02 BISPECIFIC BINDING PROTEINS FOR PD-L1 AND KDR
JP2018540412A JP2019506863A (en) 2016-02-02 2017-02-02 Double-binding protein for PD-L1 and KDR
EP17748163.7A EP3411068A4 (en) 2016-02-02 2017-02-02 Bispecific binding proteins for pd-l1 and kdr
CN201780021304.8A CN109310755A (en) 2016-02-02 2017-02-02 The bispecific binding protein of PD-L1 and KDR

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662290350P 2016-02-02 2016-02-02
US62/290,350 2016-02-02

Publications (2)

Publication Number Publication Date
WO2017136562A2 WO2017136562A2 (en) 2017-08-10
WO2017136562A3 true WO2017136562A3 (en) 2017-09-28

Family

ID=59501012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/016230 WO2017136562A2 (en) 2016-02-02 2017-02-02 Bispecific binding proteins for pd-l1 and kdr

Country Status (5)

Country Link
EP (1) EP3411068A4 (en)
JP (1) JP2019506863A (en)
CN (1) CN109310755A (en)
EA (1) EA201891732A1 (en)
WO (1) WO2017136562A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913297TA (en) 2015-03-13 2020-02-27 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
BR112019025188A2 (en) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. ACTIVABLE ANTI-PDL1 ANTIBODIES AND METHODS OF USE OF THE SAME
WO2019042153A1 (en) * 2017-09-01 2019-03-07 四川科伦博泰生物医药股份有限公司 Recombinant bispecific antibody
KR102469248B1 (en) * 2018-02-28 2022-11-22 에이피 바이오사이언시스, 아이엔씨. Bifunctional proteins with checkpoint inhibition for targeted therapy
CN113302207A (en) * 2018-11-16 2021-08-24 维尔托索宾科公司 CD38 and ICAM1 antibodies and uses thereof
CN111196856A (en) * 2018-11-19 2020-05-26 三生国健药业（上海）股份有限公司 anti-HER 2/PD1 bispecific antibodies
CN111196855B (en) * 2018-11-19 2022-11-15 三生国健药业（上海）股份有限公司 anti-EGFR/PD-1 bispecific antibodies
WO2020114355A1 (en) * 2018-12-03 2020-06-11 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd Recombinant protein targeting pd-l1 and vegf
CN109776683B (en) * 2019-03-19 2020-04-07 益科思特(北京)医药科技发展有限公司 Bispecific antibody and preparation method and application thereof
CN114286828A (en) * 2019-06-24 2022-04-05 诺华股份有限公司 Dosing regimens and combination therapies for multispecific antibodies targeting B cell maturation antigens
AU2019461286B2 (en) * 2019-08-09 2024-01-04 Anhui Biox Vision Biological Technology Co., Ltd. Anti-VEGF-anti-PD1 bispecific antibody with new-type structure
CN110498857B (en) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 anti-VEGF-anti-PD 1 bispecific antibody
CN110563849B (en) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 anti-VEGF-anti-PD 1 bispecific antibody
CN110760517B (en) * 2019-10-09 2022-04-29 天津大学 Antagonistic PD-1 camel antibody analogue AP gene, protein and application
CN113563473A (en) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 Tetravalent bispecific antibody, preparation method and application thereof
CN113754772A (en) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 Bispecific antibody for resisting PDL1 XKDR
CN113754773A (en) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 Bispecific antibody for resisting PD1 XPDL 1
CN114106190A (en) * 2020-08-31 2022-03-01 普米斯生物技术(珠海)有限公司 anti-VEGF/PD-L1 bispecific antibody and application thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060036076A1 (en) * 2003-11-19 2006-02-16 Dyax Corp. Metalloproteinase-binding proteins
US20080075726A1 (en) * 2006-08-03 2008-03-27 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies and uses thereof
US20090022736A1 (en) * 2007-05-21 2009-01-22 Reason Donald C Monoclonal Antibodies That Specifically Bind To And Neutralize Bacillus Anthracis Toxin, Compositions, And Methods Of Use
US20120269812A1 (en) * 2011-04-19 2012-10-25 Merrimack Pharmaceuticals, Inc. Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
WO2013181452A1 (en) * 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US20140234340A1 (en) * 2010-11-30 2014-08-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US20140341917A1 (en) * 2011-11-28 2014-11-20 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
WO2015066543A1 (en) * 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
WO2015109124A2 (en) * 2014-01-15 2015-07-23 Kadmon Corporation, Llc Immunomodulatory agents
US20150238601A1 (en) * 2012-10-05 2015-08-27 Kadmon Corporation, Llc Treatment of ocular disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2903618T3 (en) * 2012-10-05 2022-09-19 Kadmon Corporation, Llc Rho kinase inhibitors

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060036076A1 (en) * 2003-11-19 2006-02-16 Dyax Corp. Metalloproteinase-binding proteins
US20080075726A1 (en) * 2006-08-03 2008-03-27 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies and uses thereof
US20090022736A1 (en) * 2007-05-21 2009-01-22 Reason Donald C Monoclonal Antibodies That Specifically Bind To And Neutralize Bacillus Anthracis Toxin, Compositions, And Methods Of Use
US20140234340A1 (en) * 2010-11-30 2014-08-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US20120269812A1 (en) * 2011-04-19 2012-10-25 Merrimack Pharmaceuticals, Inc. Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
US20140341917A1 (en) * 2011-11-28 2014-11-20 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2013181452A1 (en) * 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US20150238601A1 (en) * 2012-10-05 2015-08-27 Kadmon Corporation, Llc Treatment of ocular disorders
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
WO2015066543A1 (en) * 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
WO2015109124A2 (en) * 2014-01-15 2015-07-23 Kadmon Corporation, Llc Immunomodulatory agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3411068A4 *

Also Published As

Publication number Publication date
WO2017136562A2 (en) 2017-08-10
CN109310755A (en) 2019-02-05
EA201891732A1 (en) 2019-02-28
EP3411068A2 (en) 2018-12-12
EP3411068A4 (en) 2020-01-29
JP2019506863A (en) 2019-03-14

Similar Documents

Publication Publication Date Title
WO2017136562A3 (en) Bispecific binding proteins for pd-l1 and kdr
WO2016191643A3 (en) Tigit-binding agents and uses thereof
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
CY1123163T1 (en) ANTIBODIES THAT BIND BETA KLOTHO REGION 2 AND METHODS OF USING THEM
WO2017087901A3 (en) Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
SA517381703B1 (en) Anti-C10orf54 Antibodies And Uses Thereof
WO2017184619A3 (en) Agonistic antibodies that bind human cd40 and uses thereof
PH12018501882A1 (en) Binding proteins and methods of use thereof
MX2018003689A (en) Pd-1 binding proteins and methods of use thereof.
EA201890285A1 (en) ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
WO2017091656A8 (en) Heterodimeric antibodies that bind cd3 and cd38
MX2022011002A (en) Humanized or chimeric cd3 antibodies.
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
WO2016086189A3 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
WO2016054598A3 (en) Antibodies that bind ebola glycoprotein and uses thereof
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
EA201791485A1 (en) ANTI-CD47-ANTIBODIES AND THEIR APPLICATIONS
EP3699195A3 (en) Bispecific antibodies that bind to cd38 and cd3
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
WO2016097370A3 (en) Anti-axl antagonistic antibodies
WO2016004389A3 (en) Monovalent binding proteins
WO2015197823A3 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
WO2015187521A3 (en) Anti-blys antibodies
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17748163

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2018540412

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201891732

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2017748163

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017748163

Country of ref document: EP

Effective date: 20180903